UPDATE: Jefferies Starts Dendreon (DNDN) at Underperform, Sees 35% Downside
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Jefferies initiates coverage on Dendreon Corp. (Nasdaq: DNDN) with an Underperform rating and $5 price target, suggesting 35% downside.
The firm comments, "Our analysis and survey results show Provenge to be relegated to a niche position by competition in a lucrative market with anemic sales. Near-term volatility is expected with limited sales visibility on current commercialization snags. Despite mid-term profitability, DNDN’s potentially meager cash flows are accompanied by debt overhang. Initiate with an Underperform and $5 PT."
For an analyst ratings summary and ratings history on Dendreon Corp. click here. For more ratings news on Dendreon Corp. click here.
Shares of Dendreon Corp. closed at $7.70 yesterday.
The firm comments, "Our analysis and survey results show Provenge to be relegated to a niche position by competition in a lucrative market with anemic sales. Near-term volatility is expected with limited sales visibility on current commercialization snags. Despite mid-term profitability, DNDN’s potentially meager cash flows are accompanied by debt overhang. Initiate with an Underperform and $5 PT."
For an analyst ratings summary and ratings history on Dendreon Corp. click here. For more ratings news on Dendreon Corp. click here.
Shares of Dendreon Corp. closed at $7.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Rio Tinto (RIO) at Underweight
- Evercore ISI Starts MongoDB (MDB) at Outperform
- TD Cowen Assumes Crescent Biopharma Inc (CBIO) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
